Twice-yearly HIV prevention shot succeeds in pivotal trial, but questions loom over future access
A pivotal trial in South Africa and Uganda has shown that the HIV prevention injection lenacapavir is highly effective, providing six months of protection per shot. The trial, conducted by Gilead, demonstrated that lenacapavir was superior to existing prevention pills and showed no new HIV infections among participants. Despite the promising results, questions remain about the drug's future accessibility, regulatory approval, and pricing, particularly in resource-limited countries. Gilead is working on strategies to expedite access, including licensing agreements with generic manufacturers. The study's findings have been positively received by researchers and activists, highlighting the potential to significantly reduce HIV infections among young women in high-incidence regions.

Estilo de reportagemEquilibrado
The article presents both factual information and subjective opinions, particularly regarding the potential impact and challenges of the new HIV prevention shot.

